Cormorant Asset Management, LP Portfolio Holdings

Cormorant Asset Management, LP

  • $1.3 Billion
  • Q2 2024

Cormorant Asset Management, LP has filed its 13F form on August 14, 2024 for Q2 2024 where it was disclosed a total value porftolio of $1.3 Billion distributed in 49 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Moon Lake Immunotherapeutics with a value of $373M, Arcellx, Inc. with a value of $84.2M, Vaxcyte, Inc. with a value of $83.1M, Longboard Pharmaceuticals, Inc. with a value of $75.4M, and Eye Point Pharmaceuticals, Inc. with a value of $72.4M.

Examining the 13F form we can see an decrease of $438M in the current position value, from $1.74B to 1.3B.

Cormorant Asset Management, LP is based out at Boston, MA

Below you can find more details about Cormorant Asset Management, LP portfolio as well as his latest detailed transactions.

Portfolio value $1.3 Billion
Healthcare: $1.3 Billion

Stock Holdings Table ETFs Only

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History

Summary

  • Portfolio
  • No. of Stocks 49
  • Current Value $1.3 Billion
  • Prior Value $1.74 Billion
  • Filing
  • Period Q2 2024
  • Filing Date August 14, 2024
  • Form Type 13F-HR
  • Activity in Q2 2024
  • New Purchases 8 stocks
  • Additional Purchases 11 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 11 stocks
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email